Reprogramming PDAC Stroma by Targeting Coagulation in the Tumor Microenvironment

通过靶向肿瘤微环境中的凝血来重编程 PDAC 基质

基本信息

  • 批准号:
    10681313
  • 负责人:
  • 金额:
    $ 92.8万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-01 至 2027-08-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY The overarching goal of this research program is to identify therapeutic strategies to convert the stroma of pancreatic ductal adenocarcinoma (PDAC) to a chemo- and immune-sensitive tumor microenvironment (TME). PDAC is characterized by a desmoplastic stroma that facilitates tumor growth/invasion, chemoresistance of pancreatic cancer cells (PCC), and immunosuppressive TME. Highly packed cancer-associated fibroblasts (CAFs) and dense extracellular matrix (ECM) are hallmarks of the PDAC stroma and constitute physical drug delivery barriers. Several stromal components have been targeted to enhance drug delivery, but recent studies have suggested anti-tumor roles for the stroma as complete ablation of stromal components leads to more aggressive tumors. New strategies are highly desired to reprogram stroma without compromising its anti-tumor roles. The central hypothesis is that the coagulation system in the PDAC TME can be targeted to reprogram PDAC stroma to overcome chemoresistance, drug delivery barriers, and immunosuppressive TME. Cancer- associated coagulation has been reported as a key functional signaling pathway in PDAC. Notably, several coagulation molecular targets, including thrombin, protease-activated receptor 1 (PAR1), and fibrinogen/fibrin, have been implicated in important roles contributing to tumor progression and therapeutic resistance. Specifically, it is hypothesized that the thrombin-PAR1 signaling axis can be targeted to suppress PCC growth/invasion and CAF growth/fibrosis. In addition, thrombin-mediated fibrin deposition can be targeted to suppress the drug delivery barrier and immunosuppressive TAM activities, which suppresses anti-tumor T cell activities. This hypothesis will be tested mechanistically and evaluated for translational potential by pursuing the following two integrated aims: Aim 1) Mechanistic Research: Determine the contribution of the coagulation targets in the PDAC TME. Specifically, the team will determine the role of thrombin-PAR1 signaling axis to CAF-mediated fibrosis, thrombin-mediated fibrin deposition on drug resistance, and PAR1/fibrin on the immunosuppressive TME. Aim 2) Translational Research: Evaluate the pharmacological inhibition of the coagulation targets. Especially, the team will expand the mechanistic understanding from Aim 1 using patient- derived PDAC models with FDA-approved inhibitors of thrombin and PAR1, and fibrinogen depleting agents. The effects of pharmacological inhibition will feedback to Aim 1 to delineate the efficacy of inhibiting coagulation targets. The outcome of this research will establish a new mechanistic understanding of the role of coagulation activities in the PDAC TME. It will determine whether blockade of the coagulation is a promising strategy to reprogram the PDAC stroma and, ultimately, suppress PCC/CAF growth and improve drug delivery and efficacy.
项目摘要 这项研究计划的总体目标是确定治疗策略,以转换基质, 胰腺导管腺癌(PDAC)的化疗和免疫敏感的肿瘤微环境(TME)。 PDAC的特征在于促进肿瘤生长/侵袭的促结缔组织增生性基质, 胰腺癌细胞(PCC)和免疫抑制性TME。高度堆积的癌相关成纤维细胞 细胞外基质(CAF)和致密细胞外基质(ECM)是PDAC基质的标志, 交付障碍。几种基质成分已被靶向以增强药物递送,但最近的研究表明, 已经提出了间质的抗肿瘤作用,因为完全消融间质成分导致更多的 侵袭性肿瘤非常需要新的策略来重新编程基质而不损害其抗肿瘤活性。 角色中心假设是PDAC TME中的凝血系统可以靶向重编程 PDAC基质克服化学抗性、药物递送屏障和免疫抑制性TME。癌症- 据报道,相关凝血是PDAC中的关键功能性信号传导途径。值得注意的是, 凝血分子靶点,包括凝血酶、蛋白酶激活受体1(PAR 1)和纤维蛋白原/纤维蛋白, 在促进肿瘤进展和治疗抗性方面具有重要作用。 具体而言,假设凝血酶-PAR 1信号传导轴可被靶向以抑制PCC 生长/侵袭和CAF生长/纤维化。此外,凝血酶介导的纤维蛋白沉积可以靶向于 抑制药物递送屏障和免疫抑制性TAM活性,从而抑制抗肿瘤T细胞 活动这一假设将进行测试机制和评估的翻译潜力, 以下两个综合目的:目的1)机理研究:确定混凝的贡献 PDAC TME中的目标。具体来说,研究小组将确定凝血酶-PAR 1信号轴的作用, CAF介导的纤维化,凝血酶介导的纤维蛋白沉积对耐药,和PAR 1/纤维蛋白对 免疫抑制性TME。目的2)转化研究:评价药物的药理学抑制作用。 凝血靶点特别是,该团队将使用患者- 用FDA批准的凝血酶和PAR 1抑制剂和纤维蛋白原消耗剂衍生的PDAC模型。 药理学抑制的效果将反馈到目标1,以描述抑制的功效。 凝血靶点这项研究的结果将建立一个新的机械理解的作用, PDAC TME中的凝血活性。它将决定阻断凝血是否是一种有希望的治疗方法。 重新编程PDAC基质并最终抑制PCC/CAF生长和改善药物递送的策略 和功效。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MATTHEW J FLICK其他文献

MATTHEW J FLICK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MATTHEW J FLICK', 18)}}的其他基金

Reprogramming PDAC Stroma by Targeting Coagulation in the Tumor Microenvironment
通过靶向肿瘤微环境中的凝血来重编程 PDAC 基质
  • 批准号:
    10517972
  • 财政年份:
    2022
  • 资助金额:
    $ 92.8万
  • 项目类别:
2022 Plasminogen Activation and Extracellular Proteolysis Gordon Research Conference and Seminar
2022年纤溶酶原激活和细胞外蛋白水解戈登研究会议暨研讨会
  • 批准号:
    10386008
  • 财政年份:
    2021
  • 资助金额:
    $ 92.8万
  • 项目类别:
Mechanisms linking the plasminogen/fibrinogen axis to the pathogenesis of COVID-19
纤溶酶原/纤维蛋白原轴与 COVID-19 发病机制的联系机制
  • 批准号:
    10471424
  • 财政年份:
    2021
  • 资助金额:
    $ 92.8万
  • 项目类别:
Mechanisms linking the plasminogen/fibrinogen axis to the pathogenesis of COVID-19
纤溶酶原/纤维蛋白原轴与 COVID-19 发病机制的联系机制
  • 批准号:
    10676149
  • 财政年份:
    2021
  • 资助金额:
    $ 92.8万
  • 项目类别:
Mechanisms linking the plasminogen/fibrinogen axis to the pathogenesis of COVID-19
纤溶酶原/纤维蛋白原轴与 COVID-19 发病机制的联系机制
  • 批准号:
    10316657
  • 财政年份:
    2021
  • 资助金额:
    $ 92.8万
  • 项目类别:
Fibrin(ogen) control of metabolic inflammation and obesity
纤维蛋白(原)控制代谢炎症和肥胖
  • 批准号:
    10311076
  • 财政年份:
    2018
  • 资助金额:
    $ 92.8万
  • 项目类别:
Fibrin(ogen) control of metabolic inflammation and obesity
纤维蛋白(原)控制代谢炎症和肥胖
  • 批准号:
    10065070
  • 财政年份:
    2018
  • 资助金额:
    $ 92.8万
  • 项目类别:
Targeting the Plasminogen Activation System to Limit Pancreatic Cancer Progression and Associated Thrombosis
靶向纤溶酶原激活系统以限制胰腺癌进展和相关血栓形成
  • 批准号:
    10458582
  • 财政年份:
    2018
  • 资助金额:
    $ 92.8万
  • 项目类别:
Fibrin(ogen) control of metabolic inflammation and obesity
纤维蛋白(原)控制代谢炎症和肥胖
  • 批准号:
    10083730
  • 财政年份:
    2018
  • 资助金额:
    $ 92.8万
  • 项目类别:
Targeting the Plasminogen Activation System to Limit Pancreatic Cancer Progression and Associated Thrombosis
靶向纤溶酶原激活系统以限制胰腺癌进展和相关血栓形成
  • 批准号:
    10022502
  • 财政年份:
    2018
  • 资助金额:
    $ 92.8万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 92.8万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 92.8万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 92.8万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 92.8万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 92.8万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 92.8万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 92.8万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 92.8万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 92.8万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 92.8万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了